SG Americas Securities’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.59M Sell
47,107
-22,641
-32% -$927K ﹤0.01% 1381
2026
Q1
$2.32M Sell
69,748
-8,609
-11% -$257K ﹤0.01% 1321
2025
Q4
$2.34M Buy
78,357
+16,982
+28% +$555K ﹤0.01% 1438
2025
Q3
$2.22M Buy
61,375
+52,086
+561% +$1.72M 0.01% 894
2025
Q2
$334K Buy
9,289
+6,088
+190% +$227K ﹤0.01% 1931
2025
Q1
$126K Sell
3,201
-4,529
-59% -$152K ﹤0.01% 2880
2024
Q4
$233K Sell
7,730
-15,884
-67% -$456K ﹤0.01% 2012
2024
Q3
$552K Buy
23,614
+15,238
+182% +$333K ﹤0.01% 1601
2024
Q2
$149K Sell
8,376
-6,682
-44% -$107K ﹤0.01% 2330
2024
Q1
$229K Sell
15,058
-5,161
-26% -$82.2K ﹤0.01% 1878
2023
Q4
$345K Buy
+20,219
New +$235K ﹤0.01% 1714
2023
Q2
Sell
-197,884
Closed -$2.98M 3133
2023
Q1
$2.98M Buy
+197,884
New +$3.01M 0.03% 469
2022
Q4
Sell
-66,443
Closed -$393K 3370
2022
Q3
$393K Buy
+66,443
New +$436K ﹤0.01% 1761
2022
Q1
Sell
-12,020
Closed -$228K 3424
2021
Q4
$228K Sell
12,020
-9,876
-45% -$256K ﹤0.01% 2605
2021
Q3
$729K Buy
21,896
+16,306
+292% +$504K ﹤0.01% 2182
2021
Q2
$217K Sell
5,590
-16,022
-74% -$629K ﹤0.01% 2302
2021
Q1
$1.04M Buy
21,612
+10,009
+86% +$481K 0.01% 1514
2020
Q4
$604K Sell
11,603
-40,908
-78% -$1.38M ﹤0.01% 1845
2020
Q3
$1.41M Buy
52,511
+38,866
+285% +$894K 0.01% 992
2020
Q2
$266K Sell
13,645
-3,208
-19% -$51.7K ﹤0.01% 2614
2020
Q1
$166K Buy
+16,853
New +$213K ﹤0.01% 2646
2019
Q4
Sell
-27,266
Closed -$153K 3435
2019
Q3
$153K Sell
27,266
-3,592
-12% -$25K ﹤0.01% 2499
2019
Q2
$267K Buy
30,858
+1,481
+5% +$11.2K ﹤0.01% 2253
2019
Q1
$236K Sell
29,377
-8,908
-23% -$48.1K ﹤0.01% 2450
2018
Q4
$157K Buy
38,285
+23,263
+155% +$116K ﹤0.01% 2504
2018
Q3
$84K Buy
+15,022
New +$172K ﹤0.01% 2905
2015
Q1
Sell
-6,905
Closed -$109K 3041
2014
Q4
$109K Buy
+6,905
New +$89.9K ﹤0.01% 2863

Other funds holding TGTX

SG Americas Securities's TGTX Position: Q2 2026 in Review

SG Americas Securities reduced its TG Therapeutics (TGTX) stake by 32% in Q2 2026, selling an estimated $927K and leaving 47,107 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

SG Americas Securities first reported a position in TGTX in Q4 2014 and has held it in 27 quarters since. The position peaked at $2.98M in Q1 2023. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • SG Americas Securities held 47,107 shares of TG Therapeutics worth $2.59M as of Q2 2026.
  • SG Americas Securities sold 22,641 TG Therapeutics shares in Q2 2026, an estimated $927K.
  • TG Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1381 holding.
  • SG Americas Securities first reported a position in TG Therapeutics in Q4 2014 and has held it in 27 quarters since.
  • SG Americas Securities's TG Therapeutics position peaked at $2.98M in Q1 2023.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.